Skip to content


Dalvance, Xydalba (dalbavancin) is an unknown pharmaceutical. Dalbavancin was first approved as Dalvance on 2014-05-23. It is used to treat bacterial infections, infectious skin diseases, staphylococcal infections, and streptococcal infections in the USA. It has been approved in Europe to treat bacterial skin diseases and soft tissue infections. Dalvance's patents are valid until 2023-12-25 (FDA).
Trade Name Xydalba
Common Name Dalbavancin
Indication bacterial infections, bacterial skin diseases, infectious skin diseases, soft tissue infections, staphylococcal infections, streptococcal infections
Drug Class Vancomycin-related compounds
Get full access now